Jenna Chuan
What they argued
RecovryAI’s one-line reading of the filing.
Single-point filing on escalation-threshold calibration: asks that manufacturers justify escalation thresholds against the deployment population and care-access context rather than one error rate across settings; she states she is a premed undergraduate volunteering with a screening nonprofit, which is not a professional role, so type is public. No position stated on any of M1-M5 and no autonomy level for any function class; she cites no FDA question numbers.
Themes it raises
2 of the 21 themes in the docket.
Escalating too little and too muchFDA Q6
Equity, access and under-resourced settingsFDA Q3, Q13, Q21
Across the five cross-cutting questions
RecovryAI’s reading of the whole filing. Silence is never counted as opposition.
Patient-facing autonomyShould FDA permit patient-facing AI to act with meaningful autonomy within a defined scope?
No position stated
Proportionate evidenceShould evidence requirements scale with clinical risk rather than a uniform high bar?
No position stated
Postmarket relianceCan strong postmarket monitoring justify accepting more premarket uncertainty?
No position stated
Competency evaluationCan a device be evaluated on competency benchmarks and clinical confirmation against clinicians?
No position stated
Change controlCan devices on third-party foundation models be maintained under pre-specified change control?
No position stated
Autonomy acceptedThe highest level this filing accepts
Low-consequence work: Not stated
High-consequence work: Not stated
High-consequence work: Not stated
Machine-assisted draft, pending human review. The original submission is linked below. Read the filing on regulations.gov ↗
This filing was submitted by a member of the public. We publish our analysis here and link to the submission rather than reproducing it, and this page is not indexed by search engines. Read the full submission on regulations.gov ↗